Pipeline

Program Target/MOA Indication Research Preclinical Phase 1 Phase 2 Phase 3
Efzofitimod NRP2 agonist Pulmonary Sarcoidosis(1)

 

SSc-ILD(2)

 

Other ILD
(CTD-ILD; CHP)(3)

 

ATYR2810 NRP2/VEGF antagonist Solid Tumors

 

AARS FGFR4 modulator Fibrosis

 

DARS LTBP1 modulator Fibrosis

 

NRP2 mAbs NRP2/CCR7 antagonist Inflammation

 

NRP2/SEMA3F antagonist Inflammation

 

Program/
Target
Indication Phase
Efzofitimod (ATYR1923)
NRP2 agonist
Pulmonary Sarcoidosis(1) Phase 3
SSc-ILD(2) Phase 1
Other ILD (CTD-ILD; CHP)(3) Phase 1
ATYR2810
NRP2/VEGF antagonist
Solid Tumors Phase 1
AARS
FGFR4 modulator
Fibrosis Research
DARS
LTBP1 modulator
Fibrosis Research
NRP2 mAbs
NRP2/CCR7 antagonist
Inflammation Research
NRP2 mAbs
NRP2/SEMA3F antagonist
Inflammation Research

(1) In partnership with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILD in Japan
(2) SSc-ILD: Scleroderma-related ILD
(3) CTD-ILD: Connective Tissue Disease-ILD; CHP: Chronic Hypersensitivity Pneumonitis